Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis
about
Mucormycosis, pseudallescheriasis, and other uncommon mold infectionsThe spectrum of fungi that infects humansCombination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data.Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006.Recent advances in the treatment of mucormycosis.Human Fungal Pathogens of Mucorales and Entomophthorales.Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.Targeting iron assimilation to develop new antibacterials.Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosisCombined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity.Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.Iron overload and allogeneic hematopoietic stem-cell transplantation.Immunotherapy against invasive mold infections.Update on mucormycosis pathogenesis.Host-iron assimilation: pathogenesis and novel therapies of mucormycosis.Risk factors for mortality in patients with mucormycosisConsensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.Molecular mechanisms of mucormycosis-The bitter and the sweet.Administration of Zinc Chelators Improves Survival of Mice Infected with Aspergillus fumigatus both in Monotherapy and in Combination with Caspofungin.Iron starvation induces apoptosis in Rhizopus oryzae in vitro.Invasive rhino-orbito-cerebral mucormycosis in a diabetic patient - the need for prompt treatment.Mucormycosis: a rare fungal infection in tornado victims.Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series
P2860
Q24603297-2C52F1B0-B55B-41D6-9CA1-4275114743A9Q28652321-86AD4D0E-90A1-4CCB-BF2D-6F1E8C0C0501Q30873926-231F659A-10F1-4758-9E13-55FBB9774CA3Q33644747-0C541AF8-E021-4355-BD8A-F60C2905E6F4Q34161213-1BACE5EF-723B-49D0-A973-A1C963DBAF57Q35245238-DFD878A9-EA51-46B4-88F4-15EF83991B26Q35364288-3732A458-08A8-4369-8629-4D48024D3351Q36058200-F528D38E-4E04-4723-AE56-00E4BF62AB0AQ36211648-B1A5A48F-B7D2-4383-A16E-9A0C2CA76F8BQ36862446-AD6EF382-CFE1-4118-8F4C-F110F780365FQ36951755-1C1328A7-EC5D-45C9-9288-17F7784135E0Q37439356-01785B03-0D37-4F57-B5D7-DF2C00B0276EQ37816399-34C3FE07-51E6-4F8F-8AFF-6CD56CC78A18Q37842351-49A9FC38-490D-4B44-B755-8A544EF8E01AQ37965757-AB31F22C-4F09-4E94-BCF8-DEF292671607Q38152678-E39471F7-BB77-4DD1-8407-C2BD78BDE88DQ38245340-2C02C57D-2928-429F-A5E4-04928A340ECFQ38261678-D860A745-EBC2-487D-8E2E-3AE7E832DFD2Q38284463-05E093AC-8612-4A03-BF84-4F9307566897Q40108307-E23E79D4-1782-41EC-B50C-50524968B14DQ40617936-9499C465-CEED-4693-9025-D4A87B457273Q41364249-8E3EAADC-26FD-4956-A0C6-254E9CF291CBQ41443344-E3E0B78C-9F63-4111-9DF6-C1B55411E328Q41968745-CA4B0381-5DAA-43B4-9AF4-058EB70DB9FFQ42706346-A02C3FD1-A9B9-4843-B9F8-B8EF417E232DQ43044189-DCD0A015-A3CA-428C-BDEA-BF475A21B747Q43199274-C1C00DAB-3AF9-4F09-AC69-790529353F5DQ57821495-32FADA66-6D54-4095-A2BA-29C95662CAAB
P2860
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis
@en
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
@nl
type
label
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis
@en
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
@nl
prefLabel
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis
@en
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.
@nl
P2093
P2860
P356
P1476
Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis
@en
P2093
Anne Anglim
Ashraf S Ibrahim
Brad Spellberg
Glenn E Mathisen
Hector Bonilla
Mario Perez
Thomas J Walsh
P2860
P304
P356
10.1128/AAC.00361-09
P407
P50
P577
2009-05-11T00:00:00Z